MD logo

Pediatrix Medical Group, Inc. (MD) Análisis de Acciones

Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Cotizando a $20.98, Pediatrix Medical Group, Inc. (MD) es una empresa del sector Healthcare valorada en $1.80B. Calificado con 49/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.

Ultimo analisis: 9 feb 2026
Puntuación de IA de 49/100 Objetivo $20.67 (-1.5%) MCap $1.80B Vol 558.2K

Pediatrix Medical Group, Inc. (MD) Resumen de Asistencia Médica y Tuberías

CEOKasandra H. Rossi
Empleados4120
Sede CentralSunrise, FL, US
Año de la oferta pública inicial (OPI)1995

Pediatrix Medical Group offers specialized care for newborns, mothers, and children, leveraging a comprehensive network of physicians and a focus on high-growth pediatric subspecialties. With a P/E of 11.00 and a solid 8.4% profit margin, MD presents a compelling value proposition in the healthcare sector.

Procedencia de los datos | Datos financieros Análisis cuantitativo NASDAQ Análisis: 9 feb 2026

Tesis de Inversión

Pediatrix Medical Group presents a notable research candidate due to its specialized focus and established market presence. With a P/E ratio of 11.00 and a profit margin of 8.4%, the company demonstrates financial stability and growth potential. Key value drivers include the increasing demand for specialized pediatric and maternal care, driven by advancements in medical technology and a growing awareness of complex health issues in newborns and children. Growth catalysts include expanding service offerings within existing markets and strategic acquisitions to broaden geographic reach. The company's beta of 0.78 suggests lower volatility compared to the broader market, making it a noteworthy option for risk-averse investors. Continued focus on operational efficiency and strategic partnerships should further enhance profitability and shareholder value.

Basado en las finanzas de FMP y el análisis cuantitativo

Puntos clave

  • Market capitalization of $1.79 billion, reflecting substantial investor confidence in the company's market position.
  • P/E ratio of 11.00, indicating a potentially undervalued stock compared to its earnings.
  • Profit margin of 8.4%, demonstrating efficient operations and profitability in the healthcare services sector.
  • Gross margin of 25.8%, showcasing the company's ability to manage costs effectively.
  • Beta of 0.78, suggesting lower volatility compared to the broader market, appealing to risk-averse investors.

Competidores y Pares

Fortalezas

  • Specialized expertise in high-demand pediatric and maternal care services.
  • Extensive network of physicians and hospital partnerships.
  • Strong reputation for quality care and positive patient outcomes.
  • Established market presence and brand recognition.

Debilidades

  • Dependence on reimbursement rates and regulatory policies.
  • Potential for physician turnover and staffing challenges.
  • Geographic concentration in certain markets.
  • Exposure to medical malpractice claims and litigation.

Catalizadores

  • Upcoming: Expansion of telehealth services to improve access to care and increase revenue.
  • Ongoing: Strategic acquisitions of smaller practices to broaden geographic presence and service offerings.
  • Ongoing: Development and launch of specialized pediatric programs to attract more patients.
  • Ongoing: Enhancement of maternal-fetal medicine services to address growing demand for prenatal care.

Riesgos

  • Potential: Changes in healthcare regulations and reimbursement policies could negatively impact revenue.
  • Potential: Increased competition from other healthcare providers could erode market share.
  • Potential: Economic downturns could affect patient volumes and healthcare spending.
  • Ongoing: Medical malpractice claims and litigation could result in significant financial losses.
  • Ongoing: Physician turnover and staffing challenges could disrupt operations and impact quality of care.

Oportunidades de crecimiento

  • Expansion of Telehealth Services: Pediatrix can leverage telehealth to extend its reach to underserved areas and improve access to specialized care. The telehealth market is projected to reach $400 billion by 2028, offering a significant growth opportunity. By investing in telehealth infrastructure and virtual care programs, Pediatrix can enhance patient engagement and improve outcomes, driving revenue growth and market share.
  • Strategic Acquisitions and Partnerships: Pediatrix can pursue strategic acquisitions of smaller pediatric practices and partnerships with hospitals to expand its network and service offerings. This approach allows the company to enter new markets quickly and efficiently, leveraging existing infrastructure and expertise. Targeted acquisitions in high-growth areas can significantly boost revenue and profitability within the next 3-5 years.
  • Development of Specialized Pediatric Programs: Focusing on developing specialized programs for specific pediatric conditions, such as pediatric cardiology and neurology, can attract more patients and increase revenue. These programs can be marketed to hospitals and healthcare systems, creating a recurring revenue stream. The market for specialized pediatric care is growing, driven by advancements in medical technology and increasing awareness of complex health issues.
  • Enhancement of Maternal-Fetal Medicine Services: Expanding maternal-fetal medicine services to address the growing demand for prenatal care and high-risk pregnancy management can drive significant growth. This includes offering advanced diagnostic testing, genetic counseling, and specialized care for expectant mothers with complex medical conditions. The maternal-fetal medicine market is expected to grow at a CAGR of 6% over the next five years, presenting a substantial opportunity for Pediatrix.
  • Investment in Data Analytics and AI: Utilizing data analytics and artificial intelligence to improve clinical outcomes, optimize operations, and personalize patient care can provide a competitive advantage. By analyzing patient data, Pediatrix can identify trends, predict potential health issues, and develop targeted interventions. This can lead to improved patient satisfaction, reduced costs, and increased efficiency, driving long-term growth and profitability.

Oportunidades

  • Expansion of telehealth services to reach underserved areas.
  • Strategic acquisitions and partnerships to broaden geographic reach.
  • Development of specialized pediatric programs for specific conditions.
  • Enhancement of maternal-fetal medicine services to address growing demand.

Amenazas

  • Changes in healthcare regulations and reimbursement policies.
  • Increased competition from other healthcare providers.
  • Economic downturns affecting patient volumes and healthcare spending.
  • Potential for medical malpractice claims and litigation.

Ventajas competitivas

  • Specialized Expertise: Deep expertise in neonatal, maternal-fetal, and pediatric cardiology care creates a barrier to entry.
  • Extensive Network: A large network of physicians and hospital partnerships provides a competitive advantage.
  • Reputation: A strong reputation for quality care and positive patient outcomes enhances brand loyalty.
  • Scale: The company's size and scale allow for economies of scale and efficient operations.

Acerca de MD

Founded in 1979 and headquartered in Sunrise, Florida, Pediatrix Medical Group, Inc. has evolved into a leading provider of specialized medical care. Originally known as MEDNAX, Inc., the company rebranded in July 2022 to better reflect its core focus on pediatric and maternal health. Pediatrix operates across the United States and Puerto Rico, offering a comprehensive suite of services including neonatal care, maternal-fetal care, pediatric cardiology, and other pediatric subspecialty services. Their neonatal care focuses on premature babies and those with complications, providing clinical care within hospital units. Maternal-fetal care includes inpatient and office-based services for expectant mothers and unborn babies. Pediatric cardiology addresses congenital heart defects and acquired heart disease. The company also offers specialized services in pediatric intensive care, hospitalist care, surgery, ophthalmology, and ENT. As of February 17, 2022, Pediatrix operated a network of approximately 2,700 physicians, solidifying its position as a key player in specialized pediatric and maternal healthcare.

Qué hacen

  • Provides clinical care to premature babies and newborns with complications.
  • Offers inpatient and office-based care to expectant mothers and unborn babies.
  • Delivers pediatric cardiology care for congenital heart defects and acquired heart disease.
  • Provides specialized cardiac care to fetuses, neonates, and pediatric patients.
  • Offers pediatric subspecialty care through intensivists, hospitalists, surgeons, and ophthalmologists.
  • Supports hospitals in pediatric emergency rooms, labor and delivery areas, and nursery departments.
  • Operates a network of approximately 2,700 physicians across the United States and Puerto Rico.

Modelo de Negocio

  • Generates revenue through providing specialized medical care services.
  • Contracts with hospitals and healthcare systems to provide physician staffing and management.
  • Receives payments from insurance companies, government programs, and patients for services rendered.
  • Expands service offerings and geographic reach through strategic acquisitions and partnerships.

Contexto de la Industria

Pediatrix Medical Group operates within the medical care facilities industry, which is experiencing steady growth driven by increasing demand for specialized healthcare services. The market is characterized by a mix of large national providers and smaller regional players. Key trends include the growing prevalence of chronic conditions in children and the increasing need for specialized neonatal and maternal-fetal care. The competitive landscape includes companies like Acadia Healthcare (ACHC) and American Addiction Centers (ADUS), which focus on behavioral health, while Pediatrix specializes in pediatric and maternal care. The industry is also influenced by regulatory changes and reimbursement policies, requiring companies to adapt to evolving healthcare standards.

Clientes Clave

  • Hospitals and healthcare systems seeking specialized pediatric and maternal care services.
  • Expectant mothers requiring maternal-fetal medicine services.
  • Newborns and children needing neonatal and pediatric subspecialty care.
  • Insurance companies and government programs covering healthcare costs.
Confianza de la IA: 72% Actualizado: 9 feb 2026

Finanzas

Gráfico e información

Precio de la acción de Pediatrix Medical Group, Inc. (MD): $20.98 (-0.21, -0.99%)

Últimas noticias

Consenso de analistas

Calificación de Consenso

Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para MD.

Objetivos de Precios

Objetivo de consenso: $20.67

MoonshotScore

49/100

¿Qué significa esta puntuación?

El MoonshotScore califica el potencial de crecimiento de MD en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.

Acciones de Pediatrix Medical Group, Inc.: Preguntas Clave Respondidas

¿Cuáles son los factores clave para evaluar MD?

Pediatrix Medical Group, Inc. (MD) actualmente tiene una puntuación IA de 49/100, indicando puntuación baja. La acción cotiza a un P/E de 10.7x, por debajo del promedio del S&P 500 (~20-25x), potencialmente señalando valor. Los analistas apuntan a $20.67 (-1% desde $20.98). Fortaleza clave: Specialized expertise in high-demand pediatric and maternal care services.. Riesgo principal a monitorear: Potential: Changes in healthcare regulations and reimbursement policies could negatively impact revenue.. Esto no es asesoramiento financiero.

¿Qué es el MoonshotScore de MD?

MD actualmente puntúa 49/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.

¿Con qué frecuencia se actualizan los datos de MD?

Los precios de MD se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.

¿Qué dicen los analistas sobre MD?

Los analistas han establecido un precio objetivo de consenso de $20.67 para MD, representando un potencial bajista del 1% desde el precio actual de $20.98. La cobertura incluye calificaciones de compra, mantener y venta, estimaciones de ganancias y recientes mejoras o rebajas. Consulte la sección de Consenso de Analistas en esta página.

¿Cuáles son los riesgos de invertir en MD?

Las categorías de riesgo para MD incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Changes in healthcare regulations and reimbursement policies could negatively impact revenue.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.

¿Cuál es la relación P/E de MD?

Pediatrix Medical Group, Inc. (MD) tiene una relación P/E de 10.7, que está por debajo del promedio del mercado, lo que puede sugerir valor relativo. La relación P/E compara el precio de la acción con sus ganancias por acción. Compare con el promedio del S&P 500 (~20-25x) para contexto. Esto no es asesoramiento financiero.

¿Está MD sobrevalorada o infravalorada?

Determinar si Pediatrix Medical Group, Inc. (MD) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Su relación P/E es 10.7. Objetivo de analistas $20.67 (-1% desde el precio actual). Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.

¿Cuál es el rendimiento por dividendo de MD?

Pediatrix Medical Group, Inc. (MD) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.

Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.

Recursos Oficiales

Precio a partir de Análisis actualizado el Puntuación de IA actualizada diariamente
Fuentes de Datos y Metodología
Datos de mercado proporcionados por Financial Modeling Prep y Yahoo Finance. Análisis de IA por algoritmos propietarios de Stock Expert AI. Indicadores técnicos mediante cálculos estándar de la industria. Última actualización: .

Datos proporcionados solo con fines informativos.

Notas de análisis
  • Stock data pending update.
  • Information is based on available data as of February 9, 2026.
Fuentes de datos

Popular Stocks